Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 5/20 | 0.72 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 5/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1477098 | 0.93 | MAPKAPK5 (0.83) | MAPKAPK5PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL1476626 | 0.90 | MAPKAPK5 (0.66) | MAPKAPK5PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL12443280 | 0.90 | MAPKAPK5 (0.72) | MAPKAPK5PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL12443284 | 0.90 | MAPKAPK5 (0.89) | MAPKAPK5PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL2217060 | 0.85 | MAPKAPK5 (0.76) | MAPKAPK5PIK3CDTBK1MKNK1F9 | |
| SCHEMBL10169141 | 0.85 | MAPKAPK5 (0.70) | MAPKAPK5PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL1477011 | 0.83 | MAPKAPK5 (1.00) | MAPKAPK5PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL2217522 | 0.83 | MAPKAPK5 (0.83) | MAPKAPK5PIK3CDPIK3CAPIK3CBMTOR | |
| SCHEMBL12443700 | 0.81 | MAPKAPK5 (0.65) | MAPKAPK5PIK3CDPIK3CAMKNK1F9 | |
| SCHEMBL1476116 | 0.81 | MAPKAPK5 (0.66) | MAPKAPK5PIK3CDPIK3CAPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | ANDREWS MARTIN JAMES INGLIS | 2011-07-21 | — | — | US | disclosed |
| US-7915256-B2 | Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases | GALAPAGOS NV (BE) | 2011-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178067-A1 | TRIAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | PTGES, IL1B, PTGER1 | MAPKAPK5 5/4885PIK3CD 2861/4885PIK3CA 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.